Thermo Fisher Scientific to invest $2bn

FDA Continues Focus on Rare Disease Drug Development, Announces Evidence Principles

Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics

Novartis snaps up promising ASCVD asset with Tourmaline acquisition

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status